StockData
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. (NAMS) stock

NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.39−0.07 (-0.36%)

Close on Nov 17, 2026Market cap $2.32BP/E –Yield –

NewAmsterdam Pharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

NewAmsterdam Pharma's enterprise value was $1.80B on Nov 11, 2026, against $3.97B a year earlier. Over the last 5 years it ranged from $48.75M to $3.97B, with a median of $1.20B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.80B-44.8%
2025Dec 31, 2025$3.27B+67.9%
2024Dec 31, 2024$1.95B+339.0%
2023Dec 29, 2023$443.29M+259.1%
2022Dec 30, 2022$123.45M+153.2%
2021Dec 31, 2021$48.75M–

More NewAmsterdam Pharma figures

See a number that looks wrong?